98%
921
2 minutes
20
Introduction: The tear proteomics and neuromediators are associated with clinical dry eye parameters following refractive surgery.
Purpose: To investigate and compare the tear proteomic and neuromediator profiles following small incision lenticule extraction (SMILE) versus laser-assisted in-situ keratomileusis (LASIK).
Methods: In this randomized controlled trial with paired-eye design, 70 patients were randomized to receive SMILE in one eye and LASIK in the other eye. Tear samples were collected preoperatively, and 1 week, 1, 3, 6 and 12 months postoperatively, and were examined for protein concentration changes using sequential window acquisition of all theoretical fragment ion mass spectrometry (SWATH-MS). The data were analyzed with DAVID Bioinformatics Resources for enriched gene ontology terms and over-represented pathways. Tear neuromediators levels were correlated with clinical parameters.
Results: Post-SMILE eyes had significantly better Oxford staining scores and tear break-up time (TBUT) than post-LASIK eyes at 1 and 3 months, respectively. Tear substance P and nerve growth factor levels were significantly higher in the LASIK group for 3 months and 1 year, respectively. SMILE and LASIK shared some similar biological responses postoperatively, but there was significant up-regulation in leukocyte migration and wound healing at 1 week, humoral immune response and apoptosis at 1 month, negative regulation of endopeptidase activity at 3 to 6 months, and extracellular structure organization at 1 year in the post-LASIK eyes. Tear mucin-like protein 1 and substance P levels were significantly correlated with TBUT ( = -0.47, = -0.49, respectively).
Conclusion: Significant differences in the tear neuromediators and proteomics were observed between SMILE and LASIK, even though clinical dry eye signs have subsided and became comparable between 2 procedures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020296 | PMC |
http://dx.doi.org/10.1016/j.jare.2020.11.001 | DOI Listing |
Vestn Oftalmol
September 2025
Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia.
The etiology of uveitis, choroid inflammation, is diverse, the disease is often recurrent, difficult to treat, and frequently results in disability at a young age. Studies investigating the tear fluid composition in uveitis have revealed promising biomarkers relevant for prognosis and treatment optimization. This review presents literature data on changes in the tear fluid content of proteins involved in local immune responses, intercellular interactions, proteolytic and free radical processes, nitric oxide metabolism, and other metabolic pathways in different forms of uveitis.
View Article and Find Full Text PDFActa Neuropathol Commun
September 2025
Department of Neurology, TUM University Hospital Munich, Munich, Germany.
The diagnosis of Amyotrophic Lateral Sclerosis (ALS) remains challenging, particularly in early stages, where characteristic symptoms may be subtle and nonspecific. The development of disease-specific and clinically validated biomarkers is crucial to optimize diagnosis. Here, we explored tear fluid (TF) as a promising ALS biomarker source, given its accessibility, anatomical proximity to the brainstem as an important site of neurodegeneration, and proven discriminative power in other neurodegenerative diseases.
View Article and Find Full Text PDFJ Proteome Res
August 2025
Graduate institute of medical genomics and proteomics, National Taiwan University College of Medicine, Taipei 100, Taiwan.
Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes, with variable responses to intravitreal antivascular endothelial growth factor (VEGF) therapy. This study aimed to identify tear fluid proteins linked to treatment responsiveness. Tear fluid samples were collected from 13 patients with diabetes (21 eyes with DME), among which 9 samples were analyzed using tandem mass tag-labeled liquid chromatography-mass spectrometry, and all 21 samples were validated with ELISA.
View Article and Find Full Text PDFBMJ Open Ophthalmol
August 2025
FarmaCHUSLab Group, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain
Introduction: Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among people over 55 years of age globally, being neovascular AMD (nAMD) its most aggressive form. Its treatment consists of the use of drugs that block vascular endothelial growth factor (anti-VEGF). Proteomics may allow the identification of differentially expressed proteins between responders and non-responders to each anti-VEGF drug.
View Article and Find Full Text PDFSci Rep
August 2025
Laboratorio de Neuroinmunología, Facultad de Ciencias, Universidad San Sebastián, sede Concepción, Concepción, Chile.
The search for pathological biomarkers in biological fluids that can provide valuable insight into an individual's health status, is a relevant area of research for multiple pathologies. Currently, the use of proteomics for the identification of differences in protein expression profiles between samples from healthy subjects and patients, has emerged as a powerful strategy to improve the current diagnosis of various pathologies or propose novel therapeutic approaches. Among the biological fluids from which new pathological biomarkers can be identified, tear secretion is highly attractive, since it can be collected non-invasively and could better concentrate proteins that sensitively reflect allergic responses, owing to their exposure to environmental factors and its connection to the respiratory system.
View Article and Find Full Text PDF